A Multicenter Phase II Study of Maintenance Belantamab Mafodotin (Blenrep®) after BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Protocol No
IIT-CHHABRA-EMBRACE-MM
Phase
II
Summary

The purpose of this study is to test the safety and effectiveness of a potential new treatment
called Belantamab Mafodotin for subjects who have previously received at least three
treatments, including CAR-T therapy.

Description
Maintenance post CAR-T for MM
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL